ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 238 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,021 | -13.0% | 3,120 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $74,724 | +126550.8% | 3,120 | 0.0% | 0.00% | – |
| Q1 2023 | $59 | +227.8% | 3,120 | +169.0% | 0.00% | – |
| Q4 2022 | $18 | -99.9% | 1,160 | +2.1% | 0.00% | – |
| Q3 2022 | $18,000 | -14.3% | 1,136 | -22.6% | 0.00% | – |
| Q2 2022 | $21,000 | -86.2% | 1,467 | -76.6% | 0.00% | -100.0% |
| Q1 2022 | $152,000 | -33.0% | 6,267 | -54.1% | 0.00% | 0.0% |
| Q3 2021 | $227,000 | -36.2% | 13,648 | -6.5% | 0.00% | -50.0% |
| Q2 2021 | $356,000 | +24.5% | 14,601 | +31.6% | 0.00% | 0.0% |
| Q1 2021 | $286,000 | -51.8% | 11,091 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $593,000 | +244.8% | 11,091 | +165.8% | 0.00% | +300.0% |
| Q3 2020 | $172,000 | -43.4% | 4,172 | -33.4% | 0.00% | -66.7% |
| Q2 2020 | $304,000 | +16.5% | 6,268 | +1.4% | 0.00% | 0.0% |
| Q1 2020 | $261,000 | +0.4% | 6,182 | +1.8% | 0.00% | +50.0% |
| Q4 2019 | $260,000 | +170.8% | 6,072 | +127.4% | 0.00% | +100.0% |
| Q3 2019 | $96,000 | +43.3% | 2,670 | +6.8% | 0.00% | 0.0% |
| Q2 2019 | $67,000 | 0.0% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $67,000 | +67.5% | 2,500 | 0.0% | 0.00% | – |
| Q4 2018 | $40,000 | -23.1% | 2,500 | 0.0% | 0.00% | – |
| Q3 2018 | $52,000 | -14.8% | 2,500 | -37.5% | 0.00% | -100.0% |
| Q2 2018 | $61,000 | +96.8% | 4,000 | +185.7% | 0.00% | – |
| Q1 2018 | $31,000 | -26.2% | 1,400 | 0.0% | 0.00% | – |
| Q4 2017 | $42,000 | -41.7% | 1,400 | -26.7% | 0.00% | -100.0% |
| Q3 2017 | $72,000 | +35.8% | 1,910 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $53,000 | -65.8% | 1,910 | -57.6% | 0.00% | -50.0% |
| Q1 2017 | $155,000 | +34.8% | 4,510 | +12.8% | 0.00% | +100.0% |
| Q4 2016 | $115,000 | +259.4% | 4,000 | +300.0% | 0.00% | – |
| Q3 2016 | $32,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
| Q2 2016 | $32,000 | +14.3% | 1,000 | 0.0% | 0.00% | – |
| Q1 2016 | $28,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 25,819,768 | $972,631,000 | 7.89% |
| SECTORAL ASSET MANAGEMENT INC | 822,392 | $30,980,000 | 3.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 240,773 | $9,068,000 | 3.53% |
| HARVEY CAPITAL MANAGEMENT INC | 230,700 | $8,690,000 | 3.51% |
| Palo Alto Investors LP | 1,641,030 | $61,818,000 | 2.60% |
| GARRISON BRADFORD & ASSOCIATES INC | 73,350 | $2,763,000 | 2.31% |
| EMORY UNIVERSITY | 52,977 | $1,996,000 | 1.58% |
| Sivik Global Healthcare LLC | 120,000 | $4,520,000 | 1.54% |
| Stanley-Laman Group, Ltd. | 143,876 | $5,420,000 | 1.45% |
| ACUTA CAPITAL PARTNERS, LLC | 170,000 | $6,404,000 | 1.15% |